Suppr超能文献

超声引导下冷冻消融治疗低危乳腺癌的疗效。

Efficacy of ultrasound-guided cryoablation in treating low-risk breast cancer.

机构信息

Servicio de Radiodiagnóstico, Unidad de Patología Mamaria, Hospital Universitario La Paz, Madrid, Spain.

Servicio de Radiodiagnóstico, Unidad de Patología Mamaria, Hospital Universitario La Paz, Madrid, Spain.

出版信息

Radiologia (Engl Ed). 2023 Mar-Apr;65(2):112-121. doi: 10.1016/j.rxeng.2023.03.002.

Abstract

OBJECTIVES

The primary objective of this study to determine whether infiltrating carcinoma is present in surgical specimens obtained after ultrasound-guided cryoablation from patients with HER2-negative luminal breast cancer without positive axillary lymph nodes at ultrasound. The secondary objective is to demonstrate that placing the presurgical seed-marker immediately before cryoablation does not interfere with the disappearance of tumor cells from freezing or in the surgeon's ability to locate the tumor.

METHODS

We treated 20 patients diagnosed with unifocal HR-positive HER2-negative infiltrating ductal carcinoma measuring <2cm by means of ultrasound-guided cryoablation (ICEfx Galil, Boston Scientific) using a triple-phase (freezing‒passive thawing‒freezing; 10min each phase) protocol. All patients later underwent tumorectomy according to the routine operating-room agenda.

RESULTS

No infiltrating carcinoma cells were detected in the post-cryoablation surgical specimen in 19 patients; a focus of infiltrating carcinoma cells measuring <1mm was detected in the remaining patient.

CONCLUSION

In the near future, if confirmed in larger studies with longer follow-up, cryoablation might constitute a safe and efficacious technique for the treatment of early, low-risk infiltrating ductal carcinoma. In our series, marking with ferromagnetic seeds did not interfere with the efficacy of the procedure or of the subsequent surgical intervention.

摘要

目的

本研究的主要目的是确定在超声引导下对无超声阳性腋窝淋巴结的 HER2 阴性 luminal 乳腺癌患者进行冷冻消融后获得的手术标本中是否存在浸润性癌。次要目的是证明在冷冻消融前立即放置术前种子标记物不会干扰肿瘤细胞的冷冻消融或外科医生定位肿瘤的能力。

方法

我们采用超声引导下冷冻消融(ICEfx Galil,Boston Scientific)治疗了 20 例诊断为单灶 HR 阳性 HER2 阴性浸润性导管癌的患者,肿瘤大小<2cm,采用三相(冷冻-被动解冻-冷冻;每个阶段 10 分钟)方案。所有患者随后根据常规手术室日程安排进行肿瘤切除术。

结果

19 例患者的冷冻消融后手术标本中未检测到浸润性癌细胞;另 1 例患者检测到<1mm 的浸润性癌细胞灶。

结论

在未来,如果在具有更长随访时间的更大研究中得到证实,冷冻消融可能成为治疗早期低风险浸润性导管癌的一种安全有效的技术。在我们的系列研究中,使用铁磁种子标记不会干扰该手术的疗效或随后的手术干预。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验